Rare diseases are a major health-care burden worldwide. Very little is known about the cause, behaviour, and treatment of these disorders, and thus non-specialist health-care providers and patients are left without sufficient knowledge to manage these diseases. Up to 3 million Europeans are estimated to have a rare lung disease. Several organisations—many of which are patient led—attempt to raise the profile of rare lung diseases to improve understanding and management of these disorders. Incentives have now been introduced in the USA and Europe that encourage the pharmaceutical industry to invest in targets that might otherwise not appeal because of small target populations. Despite many intrinsic challenges and obstacles, considerable progress is constantly being made in the research and development of drugs for rare disorders

Rare (orphan) lung disease and drug development: current status and future challenges / Spagnolo, Paolo; R. M., du Bois; V., Cottin. - In: THE LANCET RESPIRATORY MEDICINE. - ISSN 2213-2600. - ELETTRONICO. - 1(6):(2013), pp. 479-487. [10.1016/S2213-2600(13)70085-7]

Rare (orphan) lung disease and drug development: current status and future challenges

SPAGNOLO, Paolo;
2013

Abstract

Rare diseases are a major health-care burden worldwide. Very little is known about the cause, behaviour, and treatment of these disorders, and thus non-specialist health-care providers and patients are left without sufficient knowledge to manage these diseases. Up to 3 million Europeans are estimated to have a rare lung disease. Several organisations—many of which are patient led—attempt to raise the profile of rare lung diseases to improve understanding and management of these disorders. Incentives have now been introduced in the USA and Europe that encourage the pharmaceutical industry to invest in targets that might otherwise not appeal because of small target populations. Despite many intrinsic challenges and obstacles, considerable progress is constantly being made in the research and development of drugs for rare disorders
2013
1(6)
479
487
Rare (orphan) lung disease and drug development: current status and future challenges / Spagnolo, Paolo; R. M., du Bois; V., Cottin. - In: THE LANCET RESPIRATORY MEDICINE. - ISSN 2213-2600. - ELETTRONICO. - 1(6):(2013), pp. 479-487. [10.1016/S2213-2600(13)70085-7]
Spagnolo, Paolo; R. M., du Bois; V., Cottin
File in questo prodotto:
File Dimensione Formato  
Lancet Resp Med_Spagnolo.pdf

Accesso riservato

Tipologia: Abstract
Dimensione 281.03 kB
Formato Adobe PDF
281.03 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/982575
Citazioni
  • ???jsp.display-item.citation.pmc??? 15
  • Scopus 44
  • ???jsp.display-item.citation.isi??? 34
social impact